Modulators of toll-like receptor 7

A method for treating or preventing a viral infection comprising:

• administering, to a patient in need thereof, a therapeutically effective amount of at least one of a compound of Formula I or II:
• wherein:
• X1 is —NH—, —O—, alkylene, substituted alkylene, alkenylene, substituted alkenylene, alkynylene, substituted alkynylene, carbocyclylene, substituted carbocyclylene, heterocyclylene, or substituted heterocyclylene;
• D is carbocyclylene or heterocyclylene;
• each L1 is independently alkylene or substituted alkylene;
• each R1 is independently —NR4R5;
• m is 1 or 2;
• L2 is a covalent bond, —NH—, —O—, or —S—;
• R2 is H, halo, alkyl, substituted alkyl, alkenyl, substituted alkenyl, carbocyclyl, substituted carbocyclyl, carbocyclylalkyl, substituted carbocyclylalkyl, arylalkyl, substituted arylalkyl, heterocyclylalkyl, substituted heterocyclylalkyl,
• —C(O)R6, —C(O)OR6, —C(O)NR7R8, —S(O)OR7, —S(O)NR7R8, —S(O)2R7, —S(O)R7, —S(O)2OR7, or —S(O)2NR7R8;
• L3 is —NH—, —O—, —S—, —N(R9)C(O)—, —S(O)2—, —S(O)—, or a covalent bond;
• R3 is alkyl, substituted alkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, heteroalkyl, substituted heteroalkyl, carbocyclyl, substituted carbocyclyl, carbocyclylalkyl, substituted carbocyclylalkyl, heterocyclyl, substituted heterocyclyl, heterocyclylalkyl, or substituted heterocyclylalkyl;
• R4 and R5 are each independently H, alkyl, substituted alkyl, carbocyclyl, substituted carbocyclyl, carbocyclylalkyl, substituted carbocyclylalkyl, heterocyclyl, substituted heterocyclyl, heterocyclylalkyl, substituted heterocyclylalkyl, —C(O)H, —C(O)R3, —S(O)R3, —S(O)2R3, —C(O)OR3, or —C(O)NR7R8;
• or
• R4 and R5, taken together with the nitrogen to which they are both attached, form a substituted or unsubstituted heterocycle;
• R6 is alkyl, substituted alkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, heteroalkyl, substituted heteroalkyl, carbocyclyl, substituted carbocyclyl, carbocyclylalkyl, substituted carbocyclylalkyl, heterocyclyl, substituted heterocyclyl, heterocyclylalkyl, or substituted heterocyclylalkyl;
• R7 and R8 are each independently H, alkyl, substituted alkyl, carbocyclyl, substituted carbocyclyl, carbocyclylalkyl, substituted carbocyclylalkyl, heterocyclyl, substituted heterocyclyl, heterocyclylalkyl, or substituted heterocyclylalkyl;
• or
• R7 and R8, taken together with the nitrogen to which they are both bonded, form a substituted or unsubstituted heterocycle;
• R9 is H, alkyl, substituted alkyl, carbocyclyl, substituted carbocyclyl, carbocyclylalkyl, substituted carbocyclylalkyl, heterocyclyl, substituted heterocyclyl, heterocyclylalkyl, or substituted heterocyclylalkyl;
• R10 is halogen, cyano, azido, nitro, alkyl, substituted alkyl, hydroxyl, amino, heteroalkyl, or substituted heteroalkyl;
• n is an integer from 0 to 5;
• and
• with the following provisos:
• (a) When X1 is —CH2—, D is 1,4-phenylene, R3-L3- is CH3CH2CH2CH2O— or CH3—O—CH2CH2—O, n=0, m=1, then NR4R5 is not:
• (1) a 4-substituted or 4,4-disubstituted piperidine or piperazine (2) —NHCH3;
• (b) When X1 is —CH2—, D is 1,4-phenylene or 1,4-piperidinylene, R3-L3- is CH3CH2CH2CH2O— or CH3—O—CH2CH2—O, n=0, m=1, then neither R4 nor R5 are substituted alkyl, substituted heterocycyl, substituted benzyl;
• and
• (c) When X1 is —CH2—, D is 2,5-pyridylene, R3-L3- is CH3CH2CH2CH2O— or CH3—O—CH2CH2—O, n=0, m=1, then NR4R5 is not pyrrolyl, piperazyl, N(CH3)2, or a pharmaceutically acceptable salt, solvate, and/or ester thereof.